Association of MMP9 with adverse features of plaque progression and residual inflammatory risk in patients with chronic coronary syndrome (CCS).
Caselli C, Di Giorgi N, Ragusa R, Lorenzoni V, Smit J, El Mahdiui M, Buechel RR, Teresinska A, Pizzi MN, Roque A, Poddighe R, Knuuti J, Schütte M, Parodi O, Pelosi G, Scholte A, Rocchiccioli S, Neglia D; SMARTool Investigators.
Caselli C, et al.
Vascul Pharmacol. 2022 Oct;146:107098. doi: 10.1016/j.vph.2022.107098. Epub 2022 Sep 12.
Vascul Pharmacol. 2022.
PMID: 36100166